BITT Provides Update on DOMab Platform and CD40 Program

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today updates on the company’s DOMab™ platform. Two DOMab CD40 antagonists (BITT-CD4D11 and BITT-CD4F10) have completed discovery and optimization and a final candidate is being selected for IND-enabling steps. BITT-CD4D11 and BITT-CD4F10 are being developed for indications in autoimmunity and inflammation including Crohn’s disease, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome. BIR2101, BITT’s anti-cancer dominant tumor necrosis factor receptor 2 (TNFR2) antagonist and most advanced antibody candidate, has completed IND-enabling steps and an IND filing is anticipated by the end of Q1 2023.

“The development of dominant antibodies to our second TNF superfamily target is a major validation for the DOMab platform,” said Russell LaMontagne, Co-Founder and Chief Executive Officer of BITT. “We will be presenting preclinical data from both the CD40 and TNFR2 programs at conferences in the first half of 2023.”

BITT’s DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. The technology’s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.

About Boston Immune Technologies and Therapeutics
Boston Immune Technologies and Therapeutics, Inc. (BITT) is a Boston, MA-based company developing a novel class of antagonist antibodies targeting TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease based on the company’s DOMab™ platform. BITT is initiating clinical trials for BIR2101, its lead candidate, which is a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2). BITT is also developing additional antibodies targeting TNF superfamily receptors for indications in inflammation, oncology and infectious disease. Learn more at: www.bostonimmunetech.com.